Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 17/20 | 0.70 |
| ▸ | NPC1 | O15118 | 16/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 11/20 | 0.70 |
| ▸ | CASP3 | P42574 | 2/20 | 0.70 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.70 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.70 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 12/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.60 |
| ▸ | TSHR | P16473 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | TP53 | P04637 | 4/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7756394 | 0.84 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL6451121 | 0.80 | KDM4E (0.60) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL6449967 | 0.80 | NPC1 (0.60) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL12419482 | 0.80 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL6452343 | 0.80 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL13091138 | 0.78 | NPC1 (0.43) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL6624611 | 0.77 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL11609635 | 0.76 | ALDH1A1 (0.59) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL3429916 | 0.75 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL13930840 | 0.75 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2CASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | RAB9A 2483/4885NPC1 59/4885SMN1; SMN2 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.